Background/aims: The relationship between patient survival and biopsy-proven acute rejection (BPAR) in liver transplant recipients with hepatitis C remains unclear. The aims of this study were to compare the characteristics of patients with and without BPAR and to identify risk factors for BPAR.
Methods: We retrospectively reviewed the records of 169 HCV-RNA-positive patients who underwent LT at three centers.
Results: BPAR occurred in 39 (23.1%) of the HCV-RNA-positive recipients after LT. The 1-, 3-, and 5-year survival rates were 92.1%, 90.3%, and 88.5%, respectively, in patients without BPAR, and 75.7%, 63.4%, and 58.9% in patients with BPAR (<0.001). Multivariate analyses showed that BPAR was associated with the non-use of basiliximab and tacrolimus and the use of cyclosporin in LT recipients with HCV RNA-positive.
Conclusion: The results of the present study suggest that the immunosuppression status of HCV-RNA-positive LT recipients should be carefully determined in order to prevent BPAR and to improve patient survival.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5066384 | PMC |
| http://dx.doi.org/10.3350/cmh.2016.0022 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Five-Year Prospective, Randomized, Open-Label Study of Standard-Dose Versus Low-Dose Prolonged-Release Tacrolimus With or Without Angiotensin-Converting Enzyme Inhibitor or Angiotensin II Receptor Blocker Post Kidney Transplantation.
Clin Transplant
January 2025
Department of Internal Medicine and Immunology, Health Sciences Centre, Winnipeg, Manitoba, Canada.
Introduction: Novel approaches to improve long-term outcomes in kidney transplant recipients are required. Here, we present the 5-year data from a multicenter, prospective, Phase 3b trial evaluating treatment outcomes with standard (STD) or low (LOW) dose prolonged-release tacrolimus (TAC) combined with ACEi/ARB or other antihypertensive therapy (OAHT) in Canadian kidney transplant recipients.
Methods: Adult de novo kidney transplant recipients were randomized 2 × 2 to STD or LOW dose TAC and ACEi/ARB or OAHT.
BK Polyomavirus DNAemia With a High DNA Load Is Associated With De Novo Donor-Specific HLA Antibodies in Kidney Transplant Recipients.
J Med Virol
November 2024
Department of Internal Medicine, Leiden University Medical Center (LUMC), Leiden, The Netherlands.
Article Synopsis
- BK polyomavirus-associated nephropathy (BKPyVAN) is a significant complication after kidney transplantation, usually managed by reducing immunosuppression when BK polyomavirus (BKPyV) is detected.
- A study involving 1,076 kidney transplant recipients found a higher risk of developing de novo donor-specific antibodies (dnDSA) in patients with high BKPyV DNA loads compared to those without, suggesting that the required immunosuppression reduction can worsen immune responses.
- While high BKPyV DNAemia increased dnDSA risk, there was no significant difference in the occurrence of biopsy-proven acute rejection (BPAR) between groups, indicating a need for better strategies to manage BKPyV infections in transplant patients.
A comparative study on outcomes of ABO-incompatible kidney transplants between robot-assisted vs. open surgery-propensity score-matched analysis: a retrospective cohort study.
BMC Nephrol
November 2024
Division of Kidney and Pancreas Transplantation, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Republic of Korea.
Article Synopsis
- Robot-assisted kidney transplantation (RAKT) is gaining popularity, but there's limited research on its effectiveness for immunologically high-risk patients, particularly those with ABO incompatibility (ABOi), compared to traditional open kidney transplantation (OKT).
- A study involving 239 living-donor transplants compared 210 ABOi-OKT cases with 29 ABOi-RAKT cases, using statistical methods to ensure valid comparisons and analyze outcomes like acute rejection and graft failure.
- Results showed similar one- and two-year survival rates and kidney function between RAKT and OKT, but RAKT had longer surgery times and cold ischemic periods, while hospital stays were shorter for RAKT, indicating it is a safe and effective
Role of Induction in a Haplomatch, Related, Low-Risk, Living-Donor Kidney Transplantation with Triple Drug Immunosuppression: A Single-Center Study.
Indian J Nephrol
August 2023
Department of Nephrology, Medanta Institute of Kidney and Urology, Medanta - The Medicity, Gurugram, Haryana, India.
Background: The role of induction in low-risk, living-donor kidney transplants being treated with tacrolimus, mycophenolate mofetil, and prednisolone is debatable.
Materials And Methods: This was a retrospective study that consisted of patients undergoing living kidney transplantation between February 2010 and June 2021 with a related haplomatch donor, with maintenance immunosuppression of tacrolimus, mycophenolate mofetil, and prednisolone. High-risk transplants, such as second or more transplants, immunologically incompatible transplants, and steroid-free transplants, were excluded.
LCP-Tacrolimus Extended-Release (Envarsus XR) Use in Adolescent and Young Adult Solid Organ Transplant Recipients.
Clin Transplant
August 2024
Nephrology, Children's Hospital Colorado, Aurora, Colorado, USA.
Introduction: Limited published experience describes once daily, extended-release tacrolimus (LCP-Tac) use in pediatric solid organ transplantation (SOT), particularly nonrenal SOT. LCP-Tac can simplify immunosuppression (IS) regimens, minimize immediate release-tacrolimus (IR-Tac)-associated adverse effects, and promote adherence. This study describes the successful use of LCP-Tac in adolescent and young adult (AYA) SOT populations.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!